Archive
592 articles, sorted by publication time.
A study in cells and nematodes places the common nutrient leucine within the precise circuitry of mitochondrial protein quality control. It points to a more direct molecular bridge between diet and cellular energy, but clinical application remains clearly distant.
An international trial presented more mature data at ASCO: in patients with head and neck cancer whose disease had already failed chemotherapy and immunotherapy, amivantamab shrank some tumors and even made them disappear on imaging. But this remains early clinical evidence, with key questions still unresolved before it can change standard treatment.
Genetics does often appear behind successful drugs, but an arXiv preprint cautions that there is still a long road from association to prediction, especially when the literature data itself may already carry echoes from after market approval.
The race for new diabetes drugs is moving from single-pathway approaches toward broader metabolic regulation; retatrutide’s late-stage data are notable, but before it can reshape clinical choices, it still needs to clear the hurdles of long-term safety and direct comparison trials.
An early-stage study points to a protein called NFIL3 in the process by which CAR T cells lose their fighting power; if this pathway can be safely regulated, solid tumor treatment may gain a new entry point for redesigning immune cells.
A cell and animal study shifts the focus from directly attacking tumors to depriving cancer cells of their ability to repair DNA; this approach is still far from the clinic, but it offers a more refined way to think about resistance to PARP inhibitors.
Drug-resistant bacteria are making older antibiotics increasingly strained; a structural biology study shows that several unrelated viruses lock the MurJ protein in place in similar ways, offering clear clues for finding new antibacterial targets, though there is still a substantial experimental road before any drug emerges.
A new method called optovolution connects evolutionary screening with light-controlled signals, allowing researchers to more quickly cultivate proteins that can switch states, distinguish colors, and even perform simple logical judgments. It remains an early-stage tool-development effort, but it opens a more dynamic design path for synthetic biology.
A study from Kyoto University and RIKEN reports that even when the protein sequence remains unchanged, which synonymous codons a genetic message uses may still determine whether mRNA persists long enough to be translated; this adds a more fine-grained explanation, beyond the sequence itself, to mechanisms of gene silencing.
An analysis of U.S. insurance data shows that GLP-1 drug use does not follow a simple path of either “continuing” or “giving up”; side effects, coverage, and specialist care may jointly determine whether patients can stay on therapy longer.
FDA pre-advisory meeting documents did not show major review gaps, giving Moderna’s mRNA flu vaccine a renewed possibility of approval; but age stratification, protective benefit, and short-term reactogenicity will still determine whether this platform can take a key step beyond COVID-19 vaccines.
uniQure has been cleared to advance review using existing early- and mid-stage data and three-year follow-up data, opening a shorter but still highly uncertain regulatory path for a rare neurodegenerative disease therapy.